GlaxoSmithKline: Bacterial Infections trials

The registry lists 35 Bacterial Infections studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 13 have results posted.

Phase 1 28Phase 2 4Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis AntibioticsNot yet recruitingNCT07371429Phase 1
• Drug-drug Interaction Study of GepotidacinCompletedNCT04493931Phase 1Results posted
• Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents SubjectsCompletedNCT04079790Phase 1Results posted
• Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)CompletedNCT03568942Phase 2Results posted
• Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic FunctionCompletedNCT03562117Phase 1Results posted
• Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting ConditionsCompletedNCT03408392Phase 1Results posted
• Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult SubjectsCompletedNCT03150082Phase 1Results posted
• To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.CompletedNCT02853435Phase 1Results posted
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830TerminatedNCT02751424Phase 1Results posted
• Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal FunctionCompletedNCT02729038Phase 1Results posted
• AUGMENTIN™ in Dental InfectionsCompletedNCT02141217Phase 4Results posted
• Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT02045797Phase 2Results posted
• Amoxicillin Bioequivalence Study Brazil - FastCompletedNCT01431989Phase 1Results posted
• Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus AureusCompletedNCT00539994Phase 2Results posted
• A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRSWithdrawnNCT05340257Phase 2
• A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting ConditionsWithdrawnNCT03329547Phase 1
• Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy SubjectsCompletedNCT02045849Phase 1
• A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult WomenWithdrawnNCT01953809Phase 1
• To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944CompletedNCT01934205Phase 1
• A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese SubjectsTerminatedNCT01818011Phase 1
• A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy VolunteersWithdrawnNCT01803399Phase 1
• A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral DoseCompletedNCT01663389Phase 1
• A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy SubjectsCompletedNCT01648179Phase 1
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy SubjectsCompletedNCT01610388Phase 1
• WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & AntibioticsCompletedNCT01587768
• A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult SubjectsCompletedNCT01262885Phase 1
• A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.WithdrawnNCT01039610Phase 1
• Relative Bioavailability Study in Healthy SubjectsCompletedNCT00924911Phase 1
• A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy SubjectsCompletedNCT00896558Phase 1
• Single Dose Escalation First Time in Human PK StudyCompletedNCT00828867Phase 1
• Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416TerminatedNCT00680485Phase 1
• To Evaluate Safety, Tolerability, Pharmacokinetics, And Food Effect Of Single Doses Of GSK945237 In Healthy SubjectsCompletedNCT00517673Phase 1
• A Three-Part Study Of GSK580416 In Healthy SubjectsCompletedNCT00427141Phase 1
• Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)CompletedNCT00358371Phase 1
• Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00259909